On May 24, the market for the anti-phlegm drug market showed a growing trend with the advance of the aging society. According to m Intranet HDM system data, 2016 key cities for the domestic public hospital respiratory medicine market scale has reached 4.66 billion yuan, up 13.66% on the previous year, showed a rapid increase. 

 

 

 

A panoramic view 

 

Chinese and western medicine is evenly divided 

 

National health development planning commission organization China CDC and other departments issued "China nutrition and chronic diseases among residents report (2015), according to the respiratory system disease mortality rate of 68/10, the 40 years of age and older copd prevalence was 9.9%. According to China's CMH data, the market for the terminal market for respiratory systems reached 124.5 billion yuan in 2015, up from 13.95 billion yuan in 2016, an increase of 12.05% over the previous year. In the market for respiratory system drugs, cough and expectorating cold medicines account for 38.96%. 

 

Overall, the market of cough and expectorant drug in our country shows the situation of Chinese and western medicine. Antitussive expectorant proprietary Chinese medicine has a cough expectorant effect is good, good taste and the characteristics of low toxic residue in domestic, doubly treasured, brand thorough popular feeling, but is longer than the drug treatment is its disadvantages. In the past two years, chemicals have been popular. The market share of the Chinese and western medicine market is small, and it is almost evenly split. 

 

The size of the expectorant is over 12 billion yuan 

 

In 2017, 171 respiratory drugs were collected in the national health care drug catalog, including 92 over-the-counter OTC drugs and 79 for respiratory medications. There were 16 drugs for expectorant and 62.5% of the expectorant. Among them, the eucalyptus, the peptic and fordostam, are new varieties. According to the data of the HDM system, the amount of anti-phlegm and cough medicine in public hospitals in China's major cities in 2016 was 15.62 billion yuan, up 13.74 percent from the previous year. 

 

Expectorant drug market on the TOP 10 drug is ammonia bromine rope, acetylcysteine, eucalyptus twist pinic enteric soft capsule, bromine has new, fu si temple, the more ammonia bromine turow, phenol a hemp that sensitive, e si temple, compound pholcodine, cefaclor br new, TOP 5 varieties has entered the national health care medicine directory. The anti-phlegm takes up nearly 90 percent of the market for expectorant cough treatment. 

 

 

 

Data analysis shows that expectorant drugs have become one of the fastest growing drug classes in China and one of the most promising drug markets in the next 10 years. 2016 domestic cities, public hospitals, public hospitals at the county level, the urban community health care, in towns and townships, entity drug stores, shop three terminal 6 big market expectorant market size of more than 12 billion yuan. 

 

varieties 

 

The total market for the lime pie is over 1 billion yuan 

 

Eucalyptus twist pinic enteric capsules is nine and Beijing pharmaceutical listed domestic exclusive varieties, products, "Mr Chernow," in 1998 won the first prize in Chinese academy of medical sciences, scientific and technological progress, belongs to the second grade national new medicine. In 2005, CFDA approved production approval, and in 2007 children's clothing was approved for sale. 

 

Eucalyptus is the same as the standard myrtle oil (the name of the name: ginotong), which is produced in Germany. With the expansion of the eucalyptus market, the import standard myrtle oil has withdrawn from the Chinese market due to the expiration of the approval. At present, the Beijing nine and the pharmaceutical eucalyptus are the only domestic varieties, the new national health care medicine catalogue in 2017. 

 

According to the HDM system, the amount of the drug used in the public hospitals of China's major cities in 2016 was 137 million yuan, up 42.44% from the previous year. In fact, the lime pinhead of the eucalyptus has entered several provinces and cities' medical and drug catalogs, and predicts that its overall market sales will be over 1 billion yuan in retail price, and the market will be available in the future. 

 

 

 

Domestic aminobromo is 54 percent 

 

Ammonium bromide bromine own new active metabolites, can promote the formation of the lung surface active substance, is a kind of dissolves phlegm drugs, relieving cough and difficulty breathing, is advantageous to the airway secretion eduction. The Mucosolvan market, which was sold by Germany's boehringer ingerheim and the Japanese emperor, was $288 million in 2015, up 2.44 percent from the previous year, according to the IMS company's global 500 blockbuster drug data. 

 

In the 1990s, the company's ammonia bromo came into the market, and the product was called "shitsuan". Domestic ammonia bromine production listed, followed in April 2017, the CFDA has approved 192 ammonia bromine production approval, changzhou SiYao, hengrui pharmaceutical, Beijing approved too in the pharmaceutical industry, rossing pharmaceutical, yangzhou three drugs, shaanxi hanjiang pharmaceutical, southwest synthetic and shiyao group eight companies such as the Italian pharmaceutical production of ammonia bromine active pharmaceutical ingredients. 

 

So far the domestic production of ammonia bromine in the preparation for 70, approved the tablet, zyban, effervescent tablets, dispersible tablet, oral disintegrating tablets, sustained-release capsules, granules, oral solution, syrup, injection, powder injection for injection, and sodium chloride injection and glucose injection 13 dosage forms. In addition, the brand "o 'brien", a brand of ammonia bromo in Hong Kong's Australian pharmaceutical factory, was registered. 

 

In 2016, according to HDM system data of the urban public hospitals ammonia bromine medicine amount to 774 million yuan, down 2.58% from a year earlier and ammonia bromine cable still occupy the expectorant drug market half. It now has 54 per cent of the domestic ammonia, with a 46.10 per cent. TOP five domestic ammonia bromine cords are: changzhou SiYao accounted for 15.50% of new horse (12.86%), tianjin, shenyang pharmaceutical drug court and a 7.29% 3.27%, hainan, yunnan longhai weicon accounted for 2.86%. According to the data, the national sample hospital market in 2016 was 91.67 per cent of the market for ammonia bromo, the oral tablet, the solution, the capsule and the granules, which accounted for 8.33%. 

 

 

 

Acetylcysteine is mainly used for injection 

 

The acetylcysteine is the classic phlegm. As the deepening of the research and widely used, further realize the acetylcysteine can make sputum glycoprotein polypeptide chain in the disulfide bond rupture, decompose glycoprotein, phlegm liquid, which were made of the deoxyribonucleic acid (DNA) at the same time, has stronger antioxidant effect and promote lung surface active substance generating mechanism. 

 

According to the HDM system, the amount of acetylcysteine, a public hospital in China's key cities, was 318 million yuan in 2016, up 68.59% from the previous year. The acetylcysteine and inhaled solution of the Zambon company in Italy have been approved by the CFDA and the product is called Fluimucil. Domestic acetylcysteine is approved for the use of six companies in expectoration for expectoration. 

 

 

 

2016 acetylcysteine in TOP 5 sales manufacturers, hangzhou people's livelihood injection ", xin tai o "occupy 63.13%, of great nations" fu Lou shi "(22.40%), guangdong people kang capsule" Yi Weishi "accounted for 7.15%, jinhua kahn's effervescent tablets 5.64%, guangdong hundred Australia granules" macau source number one "accounted for 1.49%. 

 

Bromine has a monopoly on injection 

 

The bromine has stronger phlegm solution and promotes phlegm. At present, the domestic bromine has been fully covered in the hospital terminal market. The CFDA has approved 41 companies to produce new tablets of bromine, 16 of which produce bromine. According to the HDM system, the number of new drugs in public hospitals in China's major cities was 134m in 2016, up 32 per cent from the previous year. 

 

 

 

Samples of domestic hospitals on the market, in the TOP 5 bromine has the new preparations manufacturers, jincheng hayes occupy 30.12%, Jiang Xike Aaron occupy 24.04%, shijiazhuang SiYao occupy 16.39%, anhui bbca occupy 10.42%, of its countries occupy 6.43%. The price of the new tablets is lower, the competition is fierce and the share is less. Bromine has 99.45% of the new injection. In bromine has the new injection on the market, jincheng hayes of powder injection, Jiang Xike Aaron and shijiazhuang SiYao bromine has new glucose injection monopoly market, has a very high market concentration. 

 

Fordostein entered the pre-market for expectorable market five 

 

Fordostein is a new drug for the 2017 national health care drug catalog, which belongs to cysteine derivatives, a new type of anti-phlegm and sputum solution. Fudostam was developed by Japan's SSP company, mitsubishi Welfide, and first listed in Japan on December 17, 2001. The drug is used to cover all respiratory diseases, including bronchitis. 

 

2008 years later, the CFDA approved sichuan koren, chiatai qingchunbao, jiangsu dafeng sea, topfond pharmaceutical, di sand and yichang east sun changjiang pharmaceuticals and so on more than six fu si temple oral preparation production, domestic not listed on the imported drugs. 

 

According to the data of the HDM system, the amount of oral medicine taken by the public hospital of public hospitals in China in 2016 was more than 33.3 million yuan, up 24.29 percent from the previous year. The overall market size is about 300 million yuan. The top three are: sichuan koren products occupy 64.80%, di sand pharmaceutical products occupy 21.45%, jiangsu dafeng sea products occupy 12.35%, other company's products occupy 1.4%. The dosage form was 53.73% and the tablets accounted for 46.27%.